Showing 1221-1230 of 2820 results for "".
- Evobrutinib Reduces Relapsing Multiple Sclerosis Disease Activityhttps://practicalneurology.com/news/evobrutinib-reduces-relapsing-multiple-sclerosis-disease-activity/2469723/Post-hoc analysis of data from a phase 2 study (NCT02975349) of evobrutinib (M2951; EMD Serono, Rockland, MA) reduced the volume of slowly expanding MRI lesions in participants with relapsing multiple sclerosis (MS). Slowly expanding l
- Trial Results Show Gene Therapy Causes Improvements in Children with AADC Deficiencyhttps://practicalneurology.com/news/trial-results-show-gene-therapy-causes-improvements-in-children-with-aadc-deficiency/2469710/A new analysis of clinical trial results shows that a novel gene therapy (PTC-AADC; PTC Therapeutics, South Plainfield, NJ) leads to profound improvements in children with aromatic L-amino acid decarboxylase (AADC) deficiency, a rare, intractable, and fatal disorder of the central nervous system.
- Loss of Consciousness With Concussion May Be Associated With Later Increased Disabilityhttps://practicalneurology.com/news/loss-of-consciousness-with-concussion-may-be-associated-with-later-increased-disability/2469600/According to a study published in Neurology, individuals who experienced a concussion where they lost consciousness may be more likely to have some disability or limitations later in life. The participants in the study were asked whether a physical, mental or emotional problem keeps or l
- Vamorolone Has Efficacy for Treating Duchenne Muscular Dystrophy Without Affecting Growthhttps://practicalneurology.com/news/vamorolone-has-efficacy-for-treating-duchenne-muscular-dystrophy-without-affecting-growth/2470013/In the VISION-DMD trial (NCT02760277), children with Duchenne muscular dystrophy (DMD) treated with vamorolone (ReveraGen BioPharma, Rockville, MD), had improved motor function with no negative effects on linear growth or biomarkers of
- Sargramostim Improves Motor Symptoms of Parkinson Disease in Small Phase 1 Trialhttps://practicalneurology.com/news/sargramostim-improves-motor-symptoms-of-parkinson-disease-in-small-phase-1-trial/2469597/An investigator-initiated clinical trial (NCT03790670) evaluated the use of sargramostim (Leukine; Partner Therapeutics, Lexington, MA). Improvements in MDS-UPDRS Part 3 scores, which measure motor sympto
- Validation of an Algorithmic EEG-Based Diagnostic Tool for Concussionhttps://practicalneurology.com/news/validation-of-an-algorithmic-eeg-based-diagnostic-tool-for-concussion/2469505/A study validating an EEG-based algorithmic concussion assessment tool (Concussion Index; Brainscope, Bethesda, MD) has been published in JAMA Open Network for evaluating severity of concussion
- Cannabidiol Reduces Seizures in People With Tuberous Sclerosis Complex-Related Seizures in Clinical Trialshttps://practicalneurology.com/news/cannabidiol-reduces-seizures-in-people-with-tuberous-sclerosis-complex-related-seizures-in-clinical-trials/2469097/Findings from a clinical trial (NCT02544763) presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD showed that people with tuberous sclerosis complex (TSC), a genetic condition associated with t
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of
- Eye Tracking Technology Detects Traumatic Brain Injury With Sensitivity and Specificityhttps://practicalneurology.com/news/eye-tracking-technology-detects-traumatic-brain-injury-with-sensitivity-and-specificity/2469003/Research findings published in Concussion show that measurement of horizontal saccades with eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) has a 77% sensitivity and 78% specificity for i
- Research Leaders Recognized at the 2025 MDA Clinical & Scientific Conferencehttps://practicalneurology.com/news/research-leaders-recognized-at-the-2025-mda-clinical-scientific-conference/2473814/The Muscular Dystrophy Association (MDA) recognized 2 legacy award recipients at the 2025 MDA Clinical & Scientific Conference. The awardees were honored based on their significant contributions to clinical research and community advocacy. The 2025 MDA Legacy Award for Achie